Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189

Aktis Oncology (AKTS) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to AKY-1189 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies. Generated using Aktis’ miniprotein radioconjugate platform, AKY-1189 is designed to deliver actinium-225, a highly potent alpha-emitting radioisotope, to Nectin-4 expressing tumors. Approximately 80 – 90% of urothelial cancer patients show positive expression of Nectin-4.